Key result
Cytomegalovirus myocarditis is a rarely reported manifestation of CMV end-organ disease in solid organ transplant recipients, as highlighted by two described cases and a literature review.
Why the study?
Cytomegalovirus affects 15%-30% of high-risk solid organ transplant recipients, but myocarditis is a rarely reported manifestation of CMV end-organ disease.
Case Report (n=2)
Highlights CMV myocarditis as a rare but possible manifestation of CMV end-organ disease in high-risk solid organ transplant recipients.
Answers are grounded in this paper and cite their sources.
Consider CMV myocarditis in transplant recipients with unexplained cardiac dysfunction; extends sparse case literature but leaves incidence and management open.
Cytomegalovirus (CMV) is a DNA virus of the Herpesviridae family and is estimated to affect 15%-30% of high-risk solid organ transplant recipients. Typical manifestations of CMV end-organ disease in this population include colitis, esophagitis, and pneumonitis, and myocarditis is a rarely reported manifestation. We describe two cases of CMV myocarditis in solid organ transplant recipients and review the literature regarding previously published cases of CMV myocarditis.
No takes yet. Share an insight, caveat, or question.
Scherger et al. (2020) conducted a case report in Cytomegalovirus myocarditis in solid organ transplant recipients (n=2). Cytomegalovirus infection was evaluated. Cytomegalovirus myocarditis is a rarely reported manifestation of CMV end-organ disease in solid organ transplant recipients, as highlighted by two described cases and a literature review.
Synapse has enriched 10 related papers. Consider them for comparative context: